Headlines about Coherus Biosciences (NASDAQ:CHRS) have been trending somewhat positive on Wednesday, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Coherus Biosciences earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.1642987965001 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Coherus Biosciences (NASDAQ:CHRS) remained flat at $$8.60 during trading hours on Wednesday. The company had a trading volume of 401,000 shares, compared to its average volume of 595,872. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.46 and a current ratio of 5.46. Coherus Biosciences has a 12 month low of $8.05 and a 12 month high of $29.59.

Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. equities analysts expect that Coherus Biosciences will post -4.39 EPS for the current year.

A number of analysts recently issued reports on CHRS shares. Zacks Investment Research upgraded shares of Coherus Biosciences from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Tuesday, August 15th. ValuEngine upgraded shares of Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Credit Suisse Group restated an “outperform” rating and set a $17.00 target price (down previously from $24.00) on shares of Coherus Biosciences in a research report on Wednesday, September 27th. Maxim Group restated a “buy” rating and set a $20.00 target price (down previously from $40.00) on shares of Coherus Biosciences in a research report on Friday, September 8th. Finally, Cowen restated an “outperform” rating and set a $45.00 target price on shares of Coherus Biosciences in a research report on Friday, September 8th. Three research analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $30.00.

COPYRIGHT VIOLATION NOTICE: “Coherus Biosciences (CHRS) Receiving Somewhat Favorable News Coverage, Study Shows” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/coherus-biosciences-chrs-receiving-somewhat-favorable-news-coverage-study-shows/1761633.html.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Insider Buying and Selling by Quarter for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.